SubHero Banner

Epkinly (epcoritamab-bysp) – New drug approval

May 19, 2023 - The FDA announced the approval of AbbVie’s Epkinly (epcoritamab-bysp), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

Download PDF